IN2014CN04809A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04809A
IN2014CN04809A IN4809CHN2014A IN2014CN04809A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A IN 4809CHN2014 A IN4809CHN2014 A IN 4809CHN2014A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A
Authority
IN
India
Prior art keywords
tbut
prolongs
treatment
disclosed
dry eye
Prior art date
Application number
Other languages
English (en)
Inventor
Joseph G Vehige
Peter A Simmons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN04809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014CN04809A publication Critical patent/IN2014CN04809A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4809CHN2014 2011-12-07 2012-12-07 IN2014CN04809A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17
PCT/US2012/068615 WO2013086449A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Publications (1)

Publication Number Publication Date
IN2014CN04809A true IN2014CN04809A (ja) 2015-09-18

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4809CHN2014 IN2014CN04809A (ja) 2011-12-07 2012-12-07

Country Status (28)

Country Link
US (2) US20130150324A1 (ja)
EP (5) EP4403220A3 (ja)
JP (1) JP6142419B2 (ja)
KR (1) KR102017922B1 (ja)
CN (2) CN104114152A (ja)
AR (1) AR089123A1 (ja)
AU (2) AU2012347459A1 (ja)
BR (1) BR112014013820A8 (ja)
CA (1) CA2858574C (ja)
CL (1) CL2014001518A1 (ja)
CO (1) CO6990739A2 (ja)
DK (2) DK2787969T3 (ja)
ES (2) ES2797650T3 (ja)
HK (2) HK1201458A1 (ja)
HU (2) HUE057140T2 (ja)
IL (1) IL233008A (ja)
IN (1) IN2014CN04809A (ja)
MX (1) MX355216B (ja)
MY (1) MY173378A (ja)
PH (1) PH12014501296A1 (ja)
PL (2) PL2787969T3 (ja)
PT (2) PT2787969T (ja)
RU (1) RU2014127074A (ja)
SG (1) SG11201403013VA (ja)
SI (2) SI2787968T1 (ja)
TW (1) TWI652072B (ja)
WO (2) WO2013086449A1 (ja)
ZA (1) ZA201404228B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
JOP20170147B1 (ar) 2016-07-07 2021-08-17 Salvat Lab Sa تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة
WO2018035469A1 (en) 2016-08-19 2018-02-22 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
JP7311160B2 (ja) 2017-08-18 2023-07-19 アクリビスタ エルエルシー ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物
CN112272578A (zh) 2018-04-27 2021-01-26 阿勒根公司 抗微生物功效增强且毒性降低的亚氯酸钠组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
ATE6466T1 (de) 1979-10-26 1984-03-15 Smith And Nephew Associated Companies P.L.C. Autoklavierbare emulsionen.
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
DE436726T1 (de) 1989-08-03 1992-02-06 Eisai Co., Ltd., Tokio/Tokyo Verfahren zur photostabilisierung von augenspuelloesungen sowie photostabilisierte augenspuelloesung.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
CA2199610A1 (en) 1994-09-14 1996-03-21 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing repairing corneal damage
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
DE69919379T2 (de) 1998-11-13 2005-09-08 Continental Projects Ltd. Komplexe von hyaluronic saure/carnitinen und pharmazeutische und kosmetische zusammensetzungen
JP2000159659A (ja) 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
DK2153819T3 (da) 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
AU781975B2 (en) 2000-09-14 2005-06-23 Hayashibara Co., Ltd Pharmaceutical composition for ophthalmic use
CA2428985C (en) 2000-11-08 2011-05-24 Bio-Concept Laboratories Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
JP2006504701A (ja) 2002-09-30 2006-02-09 マーク・エー・バビザイェフ 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段
US7758883B2 (en) * 2002-10-18 2010-07-20 Aqueous Pharma Limited Three layer artificial tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
KR101147046B1 (ko) * 2003-06-13 2012-05-22 알콘, 인코퍼레이티드 시너지성의 2개의 폴리머 배합물을 포함하는 안과용 조성물
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
EP1683528A4 (en) * 2003-11-10 2011-07-27 Toray Industries POLYSACCHARIDE-CONTAINING COMPOSITION AND OPHTHALMIC SOLUTION FOR STABILIZING THE TISSUE FILM
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
BRPI0808410A2 (pt) 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
WO2010141648A2 (en) * 2009-06-05 2010-12-09 Allergan, Inc. Artificial tears and therapeutic uses
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
US9314528B2 (en) 2016-04-19
CO6990739A2 (es) 2014-07-10
US20130197083A1 (en) 2013-08-01
EP2787968B1 (en) 2020-03-04
PH12014501296A1 (en) 2014-10-08
HK1201458A1 (en) 2015-09-04
MX355216B (es) 2018-04-10
AU2017265181B2 (en) 2019-06-20
EP4403220A3 (en) 2024-10-23
EP4403220A2 (en) 2024-07-24
RU2014127074A (ru) 2016-02-10
KR102017922B1 (ko) 2019-09-03
RU2018119362A (ru) 2018-11-08
CA2858574C (en) 2017-05-30
CA2858574A1 (en) 2013-06-13
EP2787969B1 (en) 2021-09-29
MY173378A (en) 2020-01-21
SI2787969T1 (sl) 2021-12-31
EP2787968A1 (en) 2014-10-15
PL2787968T3 (pl) 2020-08-24
IL233008A (en) 2017-07-31
EP3666257A1 (en) 2020-06-17
HK1203057A1 (en) 2015-10-16
SI2787968T1 (sl) 2020-08-31
RU2018119362A3 (ja) 2021-09-07
TWI652072B (zh) 2019-03-01
CN104114152A (zh) 2014-10-22
EP3981387A1 (en) 2022-04-13
KR20140107383A (ko) 2014-09-04
AU2017265181A1 (en) 2017-12-14
SG11201403013VA (en) 2014-07-30
JP6142419B2 (ja) 2017-06-07
ES2896336T3 (es) 2022-02-24
MX2014006804A (es) 2014-09-22
PT2787968T (pt) 2020-06-16
PT2787969T (pt) 2021-11-09
US20130150324A1 (en) 2013-06-13
WO2013086449A1 (en) 2013-06-13
DK2787969T3 (da) 2021-11-01
PL2787969T3 (pl) 2021-12-20
BR112014013820A2 (pt) 2017-06-13
ZA201404228B (en) 2015-12-23
DK2787968T3 (da) 2020-06-02
HUE057140T2 (hu) 2022-04-28
EP2787969A1 (en) 2014-10-15
AR089123A1 (es) 2014-07-30
CN108969482A (zh) 2018-12-11
IL233008A0 (en) 2014-07-31
CL2014001518A1 (es) 2014-10-24
HUE049489T2 (hu) 2020-09-28
WO2013086438A1 (en) 2013-06-13
TW201325633A (zh) 2013-07-01
BR112014013820A8 (pt) 2017-06-13
JP2015504860A (ja) 2015-02-16
ES2797650T3 (es) 2020-12-03
AU2012347459A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
MY171920A (en) Prevention and treatment of ocular conditions
HK1222116A1 (zh) 用於治療青光眼的能夠植入患者的眼睛內的改善的排液閥
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
HRP20130830T1 (en) A water-in-oil type emulsion for treating a disease of the eye
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
IN2014CN04809A (ja)
HK1201196A1 (en) Treatment of ocular disease
IN2014CN03123A (ja)
MX2014000781A (es) Dosis combinada fija de bimatoprost y brimonidina.
HK1186660A1 (en) A water-in-oil type emulsion for treating a disease of the eye
EP3013425A4 (en) Treatment and diagnosis of ocular disease
UY34843A (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
EP3145532A4 (en) Individualized treatment of eye disease
EP3182952A4 (en) Modifying humidity to glabrous tissue for the treatment of migraine and other conditions
HK1220144A1 (zh) -叔丁基-苄基 -氯- -氯- -乙基-苯基 -乙基 -氟- -三氟甲基-苯甲酰胺用於治療眼疾病的用途
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
MX2016005505A (es) Modulador de la proteina de transferencia de ester de colesterilo (cetp) para usarse en el tratamiento de enfermedades oculares.
HK1216233A1 (zh) 含有四氫吡喃基氨基環戊基羰基四氫吡啶並吡啶衍生物作為有效成分的眼後段疾病的預防或治療劑
UA113065C2 (xx) Композиція для нанесення на шкіру та її застосування
UA111645C2 (uk) Ефективна доставка ліпідів у слізну плівку людини з використанням чутливої до солі емульсійної системи
PL401911A1 (pl) Zastosowanie preparatu o wlasciwosciach immunoregulatorowych
CN302327175S (zh) 眼镜
MX2013006527A (es) Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.